Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × defactinib × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 5 Glioblastoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Phase IB 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Lung Neoplasms 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Endometrioid 1 Brain Neoplasms 1 Advanced Colorectal Cancer 1 Adenocarcinoma of Lung 1

Interventions

Paclitaxel 56 Bevacizumab 56 Carboplatin 52 pembrolizumab 40 olaparib 31 Specimen Handling 26 niraparib 23 Gemcitabine 23 Magnetic Resonance Spectroscopy 21 Cyclophosphamide 21 Nivolumab 19 Cisplatin 18 Biopsy 18 Taxes 17 liposomal doxorubicin 16 fludarabine 14 Fulvestrant 13 Topotecan 12 Immunoglobulin G 11 Doxorubicin 11 Disulfides 11 durvalumab 10 Oxaliplatin 10 Ipilimumab 9 mirvetuximab soravtansine 8 aldesleukin 8 Fluorouracil 8 Docetaxel 8 Blood Specimen Collection 8 atezolizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06682572 2025-12-17

RAMP201J

Verastem, Inc.

Phase 2 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡